TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholder's Equity

Consolidated Statement of Changes in Stockholder's Equity	Preferred Stock [Member] USD ($)	Common Stock [Member] USD ($)	Accumulated Deficit [Member] USD ($)	Accumulated Comprehensive Loss [Member] USD ($)	Total USD ($)
Balance at Dec. 31, 2012	$ 225,000	$ 83,273,376	$ (80,194,353)		$ 3,304,023us-gaap_StockholdersEquity
Balance, shares at Dec. 31, 2012		1,278,948
Private placement of Common Shares		1,600,000			1,600,000
Private placement of Common Shares, shares		512,820
Dividends paid on Series A Convertible Preferred Stock
Conversion of Series A Preferred Stock	(225,000)	225,000
Conversion of Series A Preferred Stock, shares		320,512
Retirement of Common Shares for conversion of Series A Preferred shares		(40)			(40)
Retirement of Common Shares for conversion of Series A Preferred shares, shares		(58,515)
Private placements of Common Shares net of offering costs of $55,708		745,024			745,024
Private placements of Common Shares net of offering costs of $55,708, shares		114,072
Unrealized Gains/(Losses) on Marketable Securities
Net loss for the period			(1,526,773)		(1,526,773)us-gaap_NetIncomeLoss
Balance at Dec. 31, 2013		85,843,360	(81,721,126)		4,122,234us-gaap_StockholdersEquity
Balance, shares at Dec. 31, 2013		2,167,837
Dividends paid on Series A Convertible Preferred Stock			(15,793)	0	(15,793)us-gaap_DividendsPreferredStock
Initial public offering, net of offering costs of $1,897,164		13,101,336	0	0	13,101,336
Initial public offering, net of offering costs of $1,897,164, shares)		2,727,000
Issuance of Non-Qualified Stock Options for Directors & Officers		357,276	0	0	357,276
Issuance of Non-Qualified Stock Options for Key Employees		192,324	0	0	192,324
Issuance of Restricted Common Shares for Services		196,800	0	0	196,800
Issuance of Restricted Common Shares for Services, shares		60,000
Unrealized Gains/(Losses) on Marketable Securities				(20,124)	(20,124)
Net loss for the period		0	(3,127,167)		(3,127,167)us-gaap_NetIncomeLoss
Balance at Dec. 31, 2014		$ 99,691,096	$ (84,864,086)	$ (20,124)	$ 14,806,886us-gaap_StockholdersEquity
Balance, shares at Dec. 31, 2014		4,954,837